Phenyl c-glucoside derivative containing deoxyglucose structure, preparation method and use thereof
The present invention provides a phenyl C-glucoside derivative containing a deoxyglucose structure as represented by formula I, preparation method thereof, a pharmaceutical composition comprising the same, and uses thereof in the preparation of medicaments for treating diabetes, wherein substituents R 1 -R 7 are as defined in the specification. The present invention also provides a method for synthesizing the phenyl C-glucoside derivative containing a deoxyglucose structure and an intermediate product. The method has advantages of being simple to manage and of low cost, which is suitable for large-scale industrial production. The present invention further provides a cocrystal of (1S)-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-1,6-dideoxy-D-glucose and L-proline, and preparation method and uses thereof.
1. A compound having one of the following structures or a pharmaceutically acceptable prodrug ester thereof:
2. The compound or the pharmaceutically acceptable prodrug ester thereof according to claim 1 , wherein the pharmaceutically acceptable prodrug ester includes an ester formed by one or more hydroxyl groups on the molecule of the compound having general formula I with acetyl, pivaloyl, phosphoryl, carbamoyl and/or alkoxycarbonyl.
3. A method for preparing a compound or a pharmaceutically acceptable prodrug ester thereof according to claim 1 , the method comprising using an undeoxidized phenyl C-glucoside having the same structure as that of the target product as raw materials, when the target product is a fully deoxidized phenyl C-glucoside, the method comprises converting all the hydroxyl groups on the sugar ring into iodine with an iodizating reagent, and then removing the iodine on the sugar ring by reduction so as to obtain the target product;
when the target product is a partially deoxidized phenyl C-glucoside, the method comprises the following steps:
(1) hydroxyl protection: protecting the hydroxyl to be retained on the sugar ring with a hydroxyl protecting reagent;
(2) dehydroxylation: converting the hydroxyls to be removed on the sugar ring into iodine with an iodizating reagent, and then reducing the iodine on the sugar ring so as to remove the hydroxyls to be removed; and
(3) deprotection: removing the hydroxyl protecting group in the compound obtained in the above step so as to obtain the target product.
4. The method according to claim 3 , wherein the iodizating reagent is I 2 /triphenylphosphine/imidazole reagent.
5. The method according to claim 4 , wherein the method for reducing in the step (2) is palladium-catalyzed hydrogenation or reducing with n-Bu 3 SnH/AIBN reagent.
6. The method according to claim 5 , wherein the hydroxyl-protecting reagent is selected from one or more of acetic anhydride, acetyl chloride, tert-butyldimethylsilyl chloride (TBDMSCl), tert-butyldiphenylsilyl chloride (TBDPSCl), benzoyl chloride, p-methyl benzoyl chloride, pivaloyl chloride, (dimethoxymethyl)benzene(PhCH(OMe) 2 ), benzoic acid, 1,1,2,2-tetramethoxy cyclohexane/trimethyl orthoformate, chloroacetyl chloride and bromoacetyl chloride.
7. The method according to claim 4 , wherein the hydroxyl-protecting reagent is selected from one or more of acetic anhydride, acetyl chloride, tert-butyldimethylsilyl chloride (TBDMSCl), tert-butyldiphenylsilyl chloride (TBDPSCl), benzoyl chloride, p-methyl benzoyl chloride, pivaloyl chloride, (dimethoxymethyl)benzene(PhCH(OMe) 2 ), benzoic acid, 1,1,2,2-tetramethoxy cyclohexane/trimethyl orthoformate, chloroacetyl chloride and bromoacetyl chloride.
8. The method according to claim 3 , wherein the method for reducing in the step (2) is palladium-catalyzed hydrogenation or reducing with n-Bu 3 SnH/AIBN reagent.
9. The method according to claim 8 , wherein the hydroxyl-protecting reagent is selected from one or more of acetic anhydride, acetyl chloride, tert-butyldimethylsilyl chloride (TBDMSCl), tert-butyldiphenylsilyl chloride (TBDPSCl), benzoyl chloride, p-methyl benzoyl chloride, pivaloyl chloride, (dimethoxymethyl)benzene(PhCH(OMe) 2 ), benzoic acid, 1,1,2,2-tetramethoxy cyclohexane/trimethyl orthoformate, chloroacetyl chloride and bromoacetyl chloride.
10. The method according to claim 3 , wherein the hydroxyl-protecting reagent is selected from one or more of acetic anhydride, acetyl chloride, tert-butyldimethylsilyl chloride (TBDMSCl), tert-butyldiphenylsilyl chloride (TBDPSCl), benzoyl chloride, p-methyl benzoyl chloride, pivaloyl chloride, (dimethoxymethyl)benzene(PhCH(OMe) 2 ), benzoic acid, 1,1,2,2-tetramethoxy cyclohexane/trimethyl orthoformate, chloroacetyl chloride and bromoacetyl chloride.
11. A pharmaceutical composition, comprising a compound or a pharmaceutically acceptable prodrug ester thereof according to claim 1 , and one or more pharmaceutically acceptable carriers, excipients or diluents.
12. The composition according to claim 11 , wherein the pharmaceutically acceptable prodrug ester includes an ester formed by one or more hydroxyl groups on the molecule of the compound having general formula I with acetyl, pivaloyl, phosphoryl, carbamoyl and/or alkoxycarbonyl.
13. A method for inhibiting SGLT2 enzyme in a subject, the method comprising administering a compound or a pharmaceutically acceptable prodrug ester thereof according to claim 1 to a subject in an amount effective to inhibit SGLT2 enzyme.
14. A method for treating diabetes, the method comprising administering a therapeutically effective amount of a compound or a pharmaceutically acceptable prodrug ester thereof according to claim 1 to a patient in need of treatment.